CardiologyOnline.net

Cardiology Xagena

Dietary Magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality


Although studies have examined the association between dietary Magnesium intake and health outcome, the results are inconclusive.
Researchers have conducted a dose–response meta-analysis of prospective cohort studies in order to investigate the correlation between Magnesium intake and the risk of cardiovascular disease ( CVD ), type 2 diabetes ( T2D ), and all-cause mortality.

Forty prospective cohort studies totaling more than 1 million participants were included in the analysis.

During the follow-up periods ( ranging from 4 to 30 years ), 7678 cases of cardiovascular disease, 6845 cases of coronary heart disease ( CHD ), 701 cases of heart failure, 14,755 cases of stroke, 26,299 cases of type 2 diabetes, and 10,983 deaths were reported.

No significant association was observed between increasing dietary Magnesium intake ( per 100 mg/day increment ) and the risk of total cardiovascular disease ( RR: 0.99; 95% CI, 0.88–1.10 ) or coronary heart disease ( RR: 0.92; 95% CI, 0.85–1.01 ).

However, the same incremental increase in Magnesium intake was associated with a 22% reduction in the risk of heart failure ( RR: 0.78; 95% CI, 0.69–0.89 ) and a 7% reduction in the risk of stroke ( RR: 0.93; 95% CI, 0.89–0.97 ).

Moreover, the summary relative risks of type 2 diabetes and mortality per 100 mg/day increment in Magnesium intake were 0.81 ( 95% CI, 0.77–0.86 ) and 0.90 ( 95% CI, 0.81–0.99 ), respectively.

In conclusion, increasing dietary Magnesium intake is associated with a reduced risk of stroke, heart failure, diabetes, and all-cause mortality, but not coronary heart disease or total cardiovascular disease.
These findings support the notion that increasing dietary magnesium might provide health benefits. ( Xagena )

Xuexian Fang et al, BMC Medicine 2016; 14: 210.DOI: 10.1186/s12916-016-0742-z

XagenaMedicine_2016



Indietro